Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

41,693 stories, page 467 of 695

Advanced search

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

Takeda Announces New Assignments of Directors

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

Statement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congress

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

Takeda Reports Third-Quarter FY2025 Results | Takeda Pharmaceuticals

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

Takeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees | Takeda Pharmaceuticals

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

Takeda Phase 3 Study Results in Pediatric Ulcerative Colitis

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

U.S. FDA Accepts Takeda sBLA for Review in Pediatric UC and Crohn’s Disease

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

Rusfertides Phase 3 Trial for Polycythemia Vera at ASCO 2025

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

Takeda Presents Long-Term Data from ADVANCE-CIDP 3 Trial of HYQVIA

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

Takeda to Hold Third Quarter FY2022 Earnings Call on February 2

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

ADZYNMA® Receives European Commission Approval as First Recombinant ADAMTS13 Therapy for cTTP

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

Takeda NewsOriginal source

🇯🇵Jul 21Industrytakeda.comTier 1 · Company source

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

Takeda NewsOriginal source

🇺🇰Jul 21Regulatorygov.ukTier 1 · Regulatory source

DHSC annual statement on research integrity: 2025 to 2026

The Department of Health and Social Care’s (DHSC) annual statement on the actions it has taken to co...

UK Department of Health and Social CareOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Fugitive May Have Had Secret Career in Biotech

NewserOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

The Manila TimesOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

Pharmalittle: We're reading about Novo suing Lilly over 'deceptive' ads, a fugitive's secret life in biotech, and more

STATOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

BioSpaceOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

OKYO Pharma (Nasdaq: OKYO) to present and plan Phase 3 NCP trial

Stock TitanOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Danaher’s revenue outlook cut, biotech miss overshadow profit forecast raise

KELO-AMOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market

The Manila TimesOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Intelligent Bio Solutions Completes Precision Testing for FDA 510(k) Submission of Fingerprint Drug Screening System for Codeine Detection

Quiver QuantitativeOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?

The Globe and MailOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Israeli PolyPid signs $320 million deal to sell drug preventing surgical infections in US, Canada

The Jerusalem PostOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Biotech IPO Gains Crush AI Listings With Standout 55% Return

Bloomberg.comOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?

The Motley FoolOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Ultragenyx Pharmaceutical Stock Slides 20% With A 9-Day Losing Spree

TrefisOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Fingerprint Drug Screen Shows Repeatable Results in 1,600 Tests

Stock TitanOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

Agios says adios to sickle cell program over lackluster data

Fierce BiotechOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

FDA approves MSD’s Lipfendra as first oral PCSK9 inhibitor

European Pharmaceutical ReviewOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?

Yahoo FinanceOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

PharmaTher Partners with KetaMist Inventor to Accelerate FDA Approval of Needle-Free Ketamine Therapy

Kalkine MediaOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

Opinion: The FDA’s 505(b)(2) pathway is an underestimated engine of value creation

BioSpaceOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Lilly’s $2.8 Billion Bet on Psychedelics Buys Science That Conventional Trial Infrastructure May Not Be Able to Run

The Clinical Trial VanguardOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

The Manila TimesOriginal source

🌍Jul 21Mediascience37.comTier 2 · Direct publisher

PatientsLikeMe and Science 37 Partner to Unlock Trial Access for Interested, Eligible Patients

Science 37Original source

🇺🇸Jul 21Researchchildrenshospital.orgTier 2 · Direct publisher

Boston Children’s, Broad Institute, and The Jackson Laboratory launch the Center for Therapeutic Genetics, a non-profit effort to develop genetic medicines for rare and ultra-rare diseases

The new collaboration aims to develop precision medicines, including base and prime editing, to trea...

Boston Children's HospitalOriginal source

🇨🇦Jul 21Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Shimadzu X-ray High Voltage Generators

Shimadzu Corporation has identified a potential issue in the X-ray High Voltage Generator. Contacts...

Health Canada Recalls and Safety AlertsOriginal source

🇨🇦Jul 21Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Mequ A/S ºM Warmer Leakage

A misplaced seal may cause leakage internally in the ºM Warmer device. This can lead to a shortcut o...

Health Canada Recalls and Safety AlertsOriginal source

🇨🇦Jul 21Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Cardinal Health - Presource® Kits Containing the Ritmed® Neurological Sponges

Cardinal Health was recently informed of a medical device recall from MEDICOM concerning the Ritmed®...

Health Canada Recalls and Safety AlertsOriginal source

🌍Jul 21Researchpremier-research.comTier 2 · Direct publisher

Designing Dermatology Trials for Durable Disease Control

Premier ResearchOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Verrica deal could bring YCANTH to Israeli children if approved

Stock TitanOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Helus Pharma Announces Completion of Enrollment in Phase 3 APPROACH Study of HLP003 in Major Depressive Disorder

Quiver QuantitativeOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange

Macau BusinessOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw By Investing.com

Investing.com AustraliaOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Cold Spring Biotech Showcases Blood-Based pTau217 Test for Early Alzheimer's Detection

Focus TaiwanOriginal source

🇺🇸Jul 21Industryinvestors.abeonatherapeutics.comTier 1 · Company source

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Abeona TherapeuticsOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

Jasper and Kira merge to build immune-focused biotech

pharmaphorumOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

The Manila TimesOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw

Investing.comOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Summer registration exam pass rate highest since 2021

The Pharmaceutical JournalOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

PharmAla Biotech Executes Definitive License Agreement

GlobeNewswireOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

The Manila TimesOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange

Yahoo Finance UKOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong

Fierce BiotechOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

OKYO Pharma Chairman Gabriele Cerrone Boosts Stake to 20.51% with $35,000 Share Acquisition Ahead of Phase 3 Trial

Kalkine MediaOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Healthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listing

South China Morning PostOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

PR NewswireOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

PBS Biotech Wins 2026 Cell Products Development of the Year Award

PR NewswireOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

PharmAla Retains ALA-002 Rights Outside U.S. in Jupiter License

Stock TitanOriginal source